BeiGene lines up a next-gen CT­LA-4 to com­ple­ment its PD-1 pil­lar in new deal worth up to $270M

BeiGene is jump­ing on the band­wag­on for PD-(L)1/CT­LA-4 com­bos — with a twist.

Through a de­vel­op­ment and com­mer­cial­iza­tion pact with San Diego-based BioAt­la, BeiGene is pair­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER